'I’m a liver specialist - here's the number one common symptom of fatty liver disease'
Around a third of adults in the UK are thought to have the early stages of fatty liver disease. (Source: Daily Express - Health)
Source: Daily Express - Health - February 20, 2024 Category: Consumer Health News Source Type: news
Critical misconceptions and knowledge gaps regarding alcohol cessation and risk of relapse in alcohol-related liver disease patients: a qualitative mental models study - Mellinger JL, Winder GS, Fernandez AC, Asefah H, Zikmund-Fisher BJ.
INTRODUCTION: Despite the mortality benefits of alcohol cessation and alcohol treatment, few patients with alcohol-related liver disease (ALD) get such treatment. To understand reasons for low treatment rates, we performed a qualitative mental models study... (Source: SafetyLit)
Source: SafetyLit - February 19, 2024 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Willingness to reduce alcohol consumption predicted by short-form video exposure, media involvement, psychological bias, and cognitive factor - Chung D, Meng Y.
INTRODUCTION: Through previous studies, Chinese college students are known to be prone to alcohol consumption, which can lead to health-risk behaviors such as high blood pressure, heart disease, stroke, liver disease, and digestive problems. However, littl... (Source: SafetyLit)
Source: SafetyLit - February 19, 2024 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
SGLT2 Inhibitors Tied to Better NAFLD Outcomes vs Other Antidiabetic Agents
(MedPage Today) -- In adults with both type 2 diabetes and nonalcoholic fatty liver disease (NAFLD), the use of SGLT2 inhibitors was linked to NAFLD regression and a lower incidence of poor liver-related outcomes, according to a retrospective cohort... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 14, 2024 Category: Primary Care Source Type: news
Gilead to Buy Liver Disease Biotech After String of Disappointments
(Source: Reuters: Health)
Source: Reuters: Health - February 12, 2024 Category: Consumer Health News Source Type: news
Gilead to snap up liver disease biotech CymaBay for $4.3B
Gilead is betting $4.3 billion on a biotech six months before the FDA is expected to make an approval decision on its rare liver disease drug candidate. The California big biotech will pay cash to buy CymaBay Therapeutics, the companies said Monday morning. The deal is for…#gilead #fda #expected #cymabay #seladelpar #pbc #unlock (Source: Reuters: Health)
Source: Reuters: Health - February 12, 2024 Category: Consumer Health News Source Type: news
Gilead Snags A Top-Notch Biotech For $4.3 Billion
stock skyrocketed Monday after Gilead Sciences (GILD) announced it will buy it for $4.3 billion. The smaller biotech company is working on a treatment for a liver disease called primary biliary cholangitis. Recent testing suggests CymaBay's seladelpar could improve the hallmark itching associated…#gileadsciences #gild #cymabay #pbc #gilead #danieloday #allisongatlin #ibdagatlin #trackandbuy (Source: Reuters: Health)
Source: Reuters: Health - February 12, 2024 Category: Consumer Health News Source Type: news
Some Alcohol-Related Hospitalizations Tied to Poor Outcomes Some Alcohol-Related Hospitalizations Tied to Poor Outcomes
Patients hospitalized for alcohol-related harms are a diverse population, and those with liver disease face the highest risks for in-hospital and post-discharge mortality.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - February 12, 2024 Category: Psychiatry Tags: Psychiatry Source Type: news
'I'm a liver doctor - here are five signs of a fatty liver you need to look out for'
The doctor's warning comes amid rising cases of fatty liver disease in the UK. (Source: Daily Express - Health)
Source: Daily Express - Health - February 11, 2024 Category: Consumer Health News Source Type: news
Liver Stiffness, Fibrosis Tied to T2DM in MASLD Liver Stiffness, Fibrosis Tied to T2DM in MASLD
Significant fibrosis, as measured by FibroScan, was independently linked to type 2 diabetes in patients with metabolic dysfunction-associated steatotic liver disease.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 7, 2024 Category: Endocrinology Tags: Gastroenterology Source Type: news
Machine Learning Helps Predict HCC Risk in MASLD Machine Learning Helps Predict HCC Risk in MASLD
A machine learning model can help estimate the risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2024 Category: Cancer & Oncology Tags: Gastroenterology Source Type: news
Mindray inks strategic agreement with Aegle
Mindray North America has inked a distribution agreement with Ohio-based Aegle Medical Solutions.Under terms of the agreement, Aegle Medical Solutions will be the sole distributor of Mindray's Hepatus-Series Transient Elastography Diagnostic Ultrasound systems for noninvasive liver disease management. Mindray maintains global headquarters in Shenzhen, China. Mindray North America is located in Mahwah, NJ, and the company operates an ultrasound Innovation Center in San Jose, CA. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 2, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Product News Source Type: news
Fatty liver disease can be 'prevented or reversed' with three diet changes, says expert
Three surprising and simple dietary changes are "the best ways" to both prevent or reverse liver damage, according to a dietician. (Source: Daily Express - Health)
Source: Daily Express - Health - February 2, 2024 Category: Consumer Health News Source Type: news
Cheating death: How cancer cells escape
Cell death is fundamental to life and, thus, healthy aging. In the realm of cellular biology, ferroptosis (a form of programmed cell death) has emerged not only as a focal point of research for its potential in eliminating cancer cells, but also its role in a plethora of other diseases, including neurodegenerative diseases such as Alzheimer's disease, eye diseases such as Retinitis pigmentosa and age-related macular degeneration, as well as ischemia, cardiovascular disease, liver disease, acute kidney injury and inflammation. (Source: World Pharma News)
Source: World Pharma News - February 2, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Women Have Greater Mortality With Alcohol-Related Liver Disease
THURSDAY, Feb. 1, 2024 -- Women with fatty liver disease related to alcohol consumption have almost twice the risk for dying within a certain time period than men with the same condition, according to a letter to the editor published in the February... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2024 Category: Pharmaceuticals Source Type: news
